Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Sponsor: Peking University First Hospital
Summary
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.
Official title: Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-04
Completion Date
2029-03
Last Updated
2026-04-29
Healthy Volunteers
Yes
Conditions
Interventions
18F-T2 PET/CT
18F-T2 is injected intravenously with a dose of 0.05-0.10 mCi/kg. The CT and PET imaging session will begin approximately 60 minutes after 18F-T2 administration.
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China